CLAIMS

1. Use of a therapeutically effective amount of a polypeptide comprising a growth hormone, one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus of said growth hormone, and two chorionic gonadotrophin CTPs attached to the carboxy terminus of said growth hormone, for the preparation of a medicament for inducing weight loss or decreasing body fat in a human subject, wherein said growth hormone is administered at a dose of 0.05-7.2 mg /administration.

2. The use of claim 1, wherein at least one CTP is glycosylated.

3. The use of claim 1, wherein at least one CTP is truncated.

4. The use of claim 1, wherein at least one CTP is attached to said growth hormone via a linker.

5. The use of claim 4, wherein said linker is a peptide bond.

~~6. Use of a therapeutically effective amount of a polypeptide comprising a growth hormone, one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus of said growth hormone, and two chorionic gonadotrophin CTPs attached to the carboxy terminus of said growth hormone, for the preparation of a medicament for increasing insulin-like growth factor (IGF-1) levels in a human subject.~~

~~7. Use of one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus of said growth hormone and two chorionic gonadotrophin CTPs to the carboxy terminus of said growth hormone, for the preparation of a medicament for reducing the dosing frequency of a growth hormone in a human subject.~~

~~8. Use of a therapeutically effective amount of a polypeptide comprising a growth hormone, one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus of said growth hormone, and two chorionic gonadotrophin CTPs~~

~~attached to the carboxy terminus of said growth hormone, for the preparation of a medicament for inducing growth or weight gain in a human subject, wherein said subject is a child or adolescent.~~

~~9. The use of claim 8, wherein at least one CTP is glycosylated.~~

~~10. The use of claim 8, wherein at least one CTP is truncated.~~

~~11. The use of claim 8, wherein at least one CTP is attached to said growth hormone via a linker.~~

~~12. The use of claim 11, wherein said linker is a peptide bond.~~

~~13. Use of a therapeutically effective amount of a polypeptide comprising a growth hormone, one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus of said growth hormone, and two chorionic gonadotrophin CTPs attached to the carboxy terminus of said growth hormone, for the preparation of a medicament for maintaining insulin-like growth factor (IGF-1) levels within a normal therapeutic range in a subject.~~

~~14.~~6. The use ~~of any one~~ of claims 1, ~~6, 7, 8, and 13,~~ wherein the amino acid sequence of at least one CTP is ~~encoded by an amino acid sequence~~ selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2.

7. The use of claim 1, wherein the amino acid sequence of said polypeptide comprises the sequence set forth in amino acids 27-301 of SEQ ID NO: 11.

~~15.~~8. The use of ~~any one of~~ claims 1, ~~6, 7, 8, and 13,~~ wherein said polypeptide further comprises a signal peptide.

~~16.~~9. The use of claim 8,~~15~~ wherein said signal peptide comprises the amino acid sequence as set forth in SEQ ID NO: 3.

10. The use of claim 9, wherein the amino acid sequence of said polypeptide comprises the sequence set forth in amino acids 1-301 of SEQ ID NO: 11.

~~17.~~11. The use of ~~any one of~~ claims 1, ~~6, 7, 8, and 13,~~ wherein said growth hormone is administered once weekly or once bi-weekly.

~~18. The use of any one of claims 1, 6, 7, 8, and 13, wherein said growth hormone is administered at a dose of 0.05-7.2 mg /administration.~~

~~19.~~12. The use of ~~any one of~~ claims 1, ~~6, 7, 8, and 13,~~ wherein said growth hormone is administered at a dose of approximately 2 mg/administration.

~~20.~~13. The use ~~of any one of~~ claims ~~1, 6, 7, 8, and 13,~~ wherein said growth hormone is administered at a dose of approximately 4 mg/administration.

~~21.~~14. The use of ~~any one of~~ claims 1, ~~6, 7, 8, and 13,~~ wherein said growth hormone is administered at a dose of approximately 1.2 mg/administration.

~~22.~~15. The use of ~~any one of~~ claims 1, ~~6, 7, 8, and 13,~~ wherein said growth hormone is administered subcutaneously to said subject.